Nuvectis Pharma Inc — Cash Flow (NASDAQ:NVCT) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Cash from operating activities 13.56 M15.95 M12.25 M16.01 M 16.01 M Cash from investing activities —000 0 Cash from financing activities 27.81 M15.09 M11.65 M29.11 M 29.11 M Free cash flow 13.56 M15.95 M12.25 M16.01 M 16.01 M

News

Nuvectis initiates phase 1b trial combining NXP900 with osimertinib

Nuvectis Pharma stock rating reiterated at Buy by H.C. Wainwright

H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target

Nuvectis Pharma adds former Intra-Cellular exec to board of directors

Nuvectis initiates phase 1b program for cancer drug NXP900

Nuvectis (NVCT) Q2 Loss Widens 43%

Nuvectis Pharma stock price target lowered to $10 at H.C. Wainwright

Nuvectis halts NXP800 development for ovarian cancer, shifts focus

Nuvectis reports positive drug interaction study for cancer drug NXP900

Friday’s Insider Activity: Top Buys and Sells in US Stocks

Nuvectis Pharma: Still Interesting, But Still Too Risky To Jump In

Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference